Informations générales (source: ClinicalTrials.gov)
NeuroVascular Product Surveillance Registry (PSR) Platform (INSPIRE)
Observational [Patient Registry]
Medtronic Neurovascular Clinical Affairs (Voir sur ClinicalTrials)
décembre 2016
août 2032
10 mai 2025
Post market surveillance registry
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FONDATION A. DE ROTHSCHILD | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP Hôpital Bicêtre - Le Kremlin-Bicêtre - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier Bretagne Atlantique Vannes - Auray - 56000 - Vannes - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier Universitaire de Clermont-Ferrand - Gabriel-Montpied - 63003 - Clermont-Ferrand - France | Contact (sur clinicalTrials) | ||||
| CHRU de Tours - Hôpital Brettoneau - 37000 - Tours - France | Contact (sur clinicalTrials) | ||||
| CHU Besancon - Hôpital Jean Minjoz - Besançon - France | Contact (sur clinicalTrials) | ||||
| CHU Brest, Hôpital de la Cavale Blanche - Brest - France | Contact (sur clinicalTrials) | ||||
| CHU de Bordeaux - Centre Universitaire Pellegrin - 33000 - Bordeaux - France | Contact (sur clinicalTrials) | ||||
| CHU de Caen - Caen - France | Contact (sur clinicalTrials) | ||||
| CHU de Montpellier - Hôpital Gui de Chauliac - Montpellier - France | Contact (sur clinicalTrials) | ||||
| CHU de Nancy - Hôpital Central - 54035 - Nancy - France | Contact (sur clinicalTrials) | ||||
| CHU de Nantes Hôpital Laennec - Nantes - France | Contact (sur clinicalTrials) | ||||
| CHU Dijon Bourgogne - 21079 - Dijon - France | Contact (sur clinicalTrials) | ||||
| CHU Hôpitaux de Rouen - Hôpital Charles Nicolle - Rouen - France | Contact (sur clinicalTrials) | ||||
| CHU Limoges - Hôpital Dupuytren - Limoges - France | Contact (sur clinicalTrials) | ||||
| CHU Reims Hôpital Maison Blanche - Reims - France | Contact (sur clinicalTrials) | ||||
| CHU Toulouse - Hôpital Pierre-Paul Riquet - Toulouse - France | Contact (sur clinicalTrials) | ||||
| GHU Paris Psychiatrie & Neurosciences - 75014 - Paris - France | Contact (sur clinicalTrials) | ||||
| Hôpital de la Pitié Salpétrière - Paris - France | Contact (sur clinicalTrials) | ||||
| Hôpital de la Timone-CHU de Marseille - Marseille - France | Contact (sur clinicalTrials) | ||||
| Hôpital Pierre Wertheimer - Bron - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
For MDT16056 and MDT17077
Inclusion Criteria:
- Patient or legally authorized representative (LAR) provides authorization and/or
consent per institution and geographical requirements
- Patient has, or is intended to receive or be treated with, an eligible Medtronic
product
- Patient is consented within the enrollment window of the therapy received, as
applicable
- Patient is at least 18 years of age at time of enrollment.
Exclusion Criteria:
- Patient who is, or is expected to be inaccessible for follow-up
- Patient with exclusion criteria required by local law
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or
device study that may confound results
- Female patient who is known to be pregnant or is breastfeeding or wishes to become
pregnant during participation in the study.
For MDT24028 and MDT22032:
General Inclusion Criteria:
- Patient or legally authorized representative (LAR) provides authorization and/or
consent per institution and geographical requirements.
- Patient is treated or intended to be treated with an eligible Medtronic
Neurovascular product.
- Patient is an adult per local law at time of consent. Medtronic Business Restricted
This document is electronically controlled CONFIDENTIAL 056-F275 Rev F Clinical
Investigation Plan Template
General Exclusion Criteria:
- Patient who may be unable to complete the study follow-up
- Patient with any contraindications per the applicable Instructions for Use document
- Female patient who is known to be pregnant or is breastfeeding or wishes to become
pregnant during participation in the study
- Patient is currently enrolled in, or plans to enroll in, any concurrent drug/device
study that may confound the study results.
Additional criteria may be required, refer to cohort-specific Addendum, as applicable,
for further guidance.
Inclusion Criteria:
- Patient or legally authorized representative (LAR) provides authorization and/or
consent per institution and geographical requirements
- Patient has, or is intended to receive or be treated with, an eligible Medtronic
product
- Patient is consented within the enrollment window of the therapy received, as
applicable
- Patient is at least 18 years of age at time of enrollment.
Exclusion Criteria:
- Patient who is, or is expected to be inaccessible for follow-up
- Patient with exclusion criteria required by local law
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or
device study that may confound results
- Female patient who is known to be pregnant or is breastfeeding or wishes to become
pregnant during participation in the study.
For MDT24028 and MDT22032:
General Inclusion Criteria:
- Patient or legally authorized representative (LAR) provides authorization and/or
consent per institution and geographical requirements.
- Patient is treated or intended to be treated with an eligible Medtronic
Neurovascular product.
- Patient is an adult per local law at time of consent. Medtronic Business Restricted
This document is electronically controlled CONFIDENTIAL 056-F275 Rev F Clinical
Investigation Plan Template
General Exclusion Criteria:
- Patient who may be unable to complete the study follow-up
- Patient with any contraindications per the applicable Instructions for Use document
- Female patient who is known to be pregnant or is breastfeeding or wishes to become
pregnant during participation in the study
- Patient is currently enrolled in, or plans to enroll in, any concurrent drug/device
study that may confound the study results.
Additional criteria may be required, refer to cohort-specific Addendum, as applicable,
for further guidance.